Zacks Research Issues Negative Forecast for BAX Earnings

Baxter International Inc. (NYSE:BAX – Free Report) – Equities research analysts at Zacks Research decreased their Q4 2026 EPS estimates for shares of Baxter International in a research note issued on Thursday, November 19th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings per share of $0.59 for the quarter, down from their prior forecast of $0.60. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Baxter International’s current full-year earnings is $2.10 per share. Zacks Research also issued estimates for Baxter International’s Q1 2028 earnings at $0.44 EPS.

Baxter International (NYSE:BAX – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a negative net margin of 6.23% and a positive return on equity of 16.23%. The business had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.91 billion. During the same period in the prior year, the business posted $0.69 earnings per share. Baxter International’s revenue for the quarter was up 5.0% compared to the same quarter last year.

A number of other research firms also recently commented on BAX. Stifel Nicolaus upped their price objective on Baxter International from $19.00 to $24.00 and gave the company a “hold” rating in a report on Tuesday, July 28th. Wall Street Zen upgraded Baxter International from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Wolfe Research started coverage on Baxter International in a research note on Tuesday, October 20th. They issued a “peer perform” rating on the stock. UBS Group raised their price objective on shares of Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a research report on Tuesday, July 28th. Finally, Weiss Ratings upgraded Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, October 30th. One investment analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $23.27.

Read Our Latest Stock Report on Baxter International

Baxter International Stock Performance

NYSE BAX opened at $25.38 on Friday. The company has a 50 day moving average of $24.64 and a 200-day moving average of $21.81. The company has a current ratio of 1.79, a quick ratio of 1.19 and a debt-to-equity ratio of 1.20. The firm has a market cap of $13.13 billion, a price-to-earnings ratio of -18.00, a PEG ratio of 3.73 and a beta of 0.68. Baxter International has a 1-year low of $15.73 and a 1-year high of $30.00.

Institutional Trading of Baxter International

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp purchased a new stake in Baxter International in the 2nd quarter worth approximately $26,000. Nemes Rush Group LLC raised its position in shares of Baxter International by 2,915.9% during the 3rd quarter. Nemes Rush Group LLC now owns 1,327 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 1,283 shares in the last quarter. Global Retirement Partners LLC lifted its holdings in shares of Baxter International by 45.8% in the 3rd quarter. Global Retirement Partners LLC now owns 1,566 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 492 shares during the last quarter. Jacobi Capital Management LLC bought a new stake in Baxter International during the 3rd quarter valued at about $51,000. Finally, Silver Grove Financial Group Inc. grew its position in shares of Baxter International by 28.8% during the 3rd quarter. Silver Grove Financial Group Inc. now owns 2,031 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 454 shares in the last quarter. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Friday, November 27th will be paid a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, November 27th. Baxter International’s dividend payout ratio is -2.84%.

Recent Baxter International Headlines

These are some of the BAX headlines that stood out recently:

  • Positive Sentiment: Zacks raised its FY2026, FY2027 and FY2028 EPS forecasts to $2.09, $2.02 and $2.15, respectively. It also increased estimates for Q3 and Q4 2027 and Q3 2028, signaling improved expectations for some periods. MarketBeat report
  • Neutral Sentiment: The revisions were mixed overall, and Zacks kept its Hold rating. The adjustments are analyst forecasts rather than a change in Baxter’s business outlook or formal company guidance. MarketBeat report
  • Negative Sentiment: Zacks lowered its EPS estimates for Q4 2026, Q1 and Q2 2027, and Q2 2028. These cuts suggest softer expectations in several nearer-term periods and offset some of the upward revisions. MarketBeat report

About Baxter International

(Get Free Report)

Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.

Further Reading

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.